Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | CHIEF SCIENTIFIC OFFICER | April 09, 2026 | April 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date April 09, 2026 · Filed April 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.54 · Expires 2036-04-08 | Direct | 300,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 300,000 · Balance 300,000 F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2021 Filed Jun 10, 2021 22:41 UTC Amendment | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,152 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-21-039625 · doc4a.xml · derivative · entry 3 CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,152 shares Expires 2026-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option fully vested on September 1, 2016. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 22:41 UTC Amendment | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 3,152 | $1.04 | $3,278.08 |
DisclosureSEC source: 0001209191-21-039625 · doc4a.xml · nonDerivative · entry 2 CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed Jun 10, 2021 22:41 UTC Amendment | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 185 | $14.45 | $2,673.25 |
DisclosureSEC source: 0001209191-21-039625 · doc4a.xml · nonDerivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,166 F1 · security: The original Form 4 filed on June 9, 2021 is being amended to voluntarily report the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of October 2, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began October 2, 2020. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the initial public offering price from the issuer's initial public offering. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 22:31 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-21-012813 · doc4.xml · derivative · entry 1 CHURCH KEVIN · CIK 0001822499 · Vice President of Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-17 F1 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.